Sporanox

Blastomycosis, Paracoccidioidomycosis, Chromoblastomycosis + 15 more
Treatment
8 FDA approvals
20 Active Studies for Sporanox

What is Sporanox

ItraconazoleThe Generic name of this drug
Treatment SummaryItraconazole is an antifungal medication that stops the growth of fungi by preventing the production of a necessary component called ergosterol. This drug is used to treat infections like histoplasmosis, blastomycosis, cryptococcal meningitis, and aspergillosis.
Sporanoxis the brand name
Sporanox Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Sporanox
Itraconazole
1992
35

Approved as Treatment by the FDA

Itraconazole, otherwise known as Sporanox, is approved by the FDA for 8 uses which include Fungal skin infection and Sporotrichosis .
Fungal skin infection
Sporotrichosis
Sporotrichosis
Cellulitis
Esophageal Candidiasis
Oropharyngeal Candidiasis
Chromoblastomycosis
Paracoccidioidomycosis

Effectiveness

How Sporanox Affects PatientsItraconazole is a medication used to treat fungal infections. It works by stopping the growth of certain types of fungus by blocking the enzymes that create the cell walls. Itraconazole has been shown to be effective against Cryptococcus neoformans and Candida spp. in both normal and immunocompromised animals. It has also been used to treat systemic and intracranial fungal infections due to Cryptococcus neoformans and systemic infections due to Candida albicans.
How Sporanox works in the bodyItraconazole works by targeting an enzyme that helps build the fungal cell membrane. By blocking this enzyme, itraconazole causes the cell membrane to become leaky, allowing its contents to escape. Itraconazole has other effects as well, such as blocking respiration, preventing fungi from changing their shape, and interfering with the production of fats and lipids.

When to interrupt dosage

The endorsed dose of Sporanox is contingent upon the diagnosed disorder, including Onychomycosis, prophylaxis of Penicilliosis and Coccidioidal meningitis. The measure of dosage fluctuates, according to the administration technique delineated in the table below.
Condition
Dosage
Administration
Blastomycosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Topical, Cream, Capsule, gelatin coated, Intravenous, Kit - Intravenous, Capsule, coated pellets - Oral, Capsule, coated pellets, Solution - Topical
Paracoccidioidomycosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Topical, Cream, Capsule, gelatin coated, Intravenous, Kit - Intravenous, Capsule, coated pellets - Oral, Capsule, coated pellets, Solution - Topical
Chromoblastomycosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Topical, Cream, Capsule, gelatin coated, Intravenous, Kit - Intravenous, Capsule, coated pellets - Oral, Capsule, coated pellets, Solution - Topical
Onychomycosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Topical, Cream, Capsule, gelatin coated, Intravenous, Kit - Intravenous, Capsule, coated pellets - Oral, Capsule, coated pellets, Solution - Topical
Sporotrichosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Topical, Cream, Capsule, gelatin coated, Intravenous, Kit - Intravenous, Capsule, coated pellets - Oral, Capsule, coated pellets, Solution - Topical
Histoplasmosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Topical, Cream, Capsule, gelatin coated, Intravenous, Kit - Intravenous, Capsule, coated pellets - Oral, Capsule, coated pellets, Solution - Topical
Cellulitis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Topical, Cream, Capsule, gelatin coated, Intravenous, Kit - Intravenous, Capsule, coated pellets - Oral, Capsule, coated pellets, Solution - Topical
Coccidioidomycosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Topical, Cream, Capsule, gelatin coated, Intravenous, Kit - Intravenous, Capsule, coated pellets - Oral, Capsule, coated pellets, Solution - Topical
disseminated Other specified protozoal diseases
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Topical, Cream, Capsule, gelatin coated, Intravenous, Kit - Intravenous, Capsule, coated pellets - Oral, Capsule, coated pellets, Solution - Topical
prophylaxis of Histoplasmosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Topical, Cream, Capsule, gelatin coated, Intravenous, Kit - Intravenous, Capsule, coated pellets - Oral, Capsule, coated pellets, Solution - Topical
prophylaxis of Penicilliosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Topical, Cream, Capsule, gelatin coated, Intravenous, Kit - Intravenous, Capsule, coated pellets - Oral, Capsule, coated pellets, Solution - Topical
Aspergillosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Topical, Cream, Capsule, gelatin coated, Intravenous, Kit - Intravenous, Capsule, coated pellets - Oral, Capsule, coated pellets, Solution - Topical
Candidiasis, Vulvovaginal
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Topical, Cream, Capsule, gelatin coated, Intravenous, Kit - Intravenous, Capsule, coated pellets - Oral, Capsule, coated pellets, Solution - Topical
talaromycosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Topical, Cream, Capsule, gelatin coated, Intravenous, Kit - Intravenous, Capsule, coated pellets - Oral, Capsule, coated pellets, Solution - Topical
Coccidioides
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Topical, Cream, Capsule, gelatin coated, Intravenous, Kit - Intravenous, Capsule, coated pellets - Oral, Capsule, coated pellets, Solution - Topical
HIV
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Topical, Cream, Capsule, gelatin coated, Intravenous, Kit - Intravenous, Capsule, coated pellets - Oral, Capsule, coated pellets, Solution - Topical
Oropharyngeal Candidiasis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Topical, Cream, Capsule, gelatin coated, Intravenous, Kit - Intravenous, Capsule, coated pellets - Oral, Capsule, coated pellets, Solution - Topical
Esophageal Candidiasis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Topical, Cream, Capsule, gelatin coated, Intravenous, Kit - Intravenous, Capsule, coated pellets - Oral, Capsule, coated pellets, Solution - Topical

Warnings

Sporanox has four contraindications and should not be amalgamated with the conditions specified in the following table.Sporanox Contraindications
Condition
Risk Level
Notes
Congestive Heart Failure
Do Not Combine
Congestive heart failure
Do Not Combine
Cytochrome P450
Do Not Combine
suspected pregnancy
Do Not Combine
There are 20 known major drug interactions with Sporanox.
Common Sporanox Drug Interactions
Drug Name
Risk Level
Description
(R)-warfarin
Major
The metabolism of (R)-warfarin can be decreased when combined with Itraconazole.
(S)-Warfarin
Major
The metabolism of (S)-Warfarin can be decreased when combined with Itraconazole.
1,2-Benzodiazepine
Major
The metabolism of 1,2-Benzodiazepine can be decreased when combined with Itraconazole.
3,5-diiodothyropropionic acid
Major
The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Itraconazole.
5-androstenedione
Major
The metabolism of 5-androstenedione can be decreased when combined with Itraconazole.
Sporanox Toxicity & Overdose RiskNo life-threatening reactions were seen in mice, rats, and dogs when itraconazole was administered orally at doses of 320mg/kg and 200mg/kg respectively.
image of a doctor in a lab doing drug, clinical research

Sporanox Novel Uses: Which Conditions Have a Clinical Trial Featuring Sporanox?

137 active clinical trials are being conducted to explore the potential of Sporanox in managing Chromomycosis, Dermatomycoses and Sporotrichosis.
Condition
Clinical Trials
Trial Phases
prophylaxis of Histoplasmosis
0 Actively Recruiting
Cellulitis
0 Actively Recruiting
Sporotrichosis
0 Actively Recruiting
Onychomycosis
0 Actively Recruiting
disseminated Other specified protozoal diseases
0 Actively Recruiting
Histoplasmosis
0 Actively Recruiting
Chromoblastomycosis
0 Actively Recruiting
Paracoccidioidomycosis
0 Actively Recruiting
Coccidioidomycosis
0 Actively Recruiting
prophylaxis of Penicilliosis
0 Actively Recruiting
Candidiasis, Vulvovaginal
2 Actively Recruiting
Not Applicable, Phase 3
Coccidioides
0 Actively Recruiting
Aspergillosis
0 Actively Recruiting
Esophageal Candidiasis
0 Actively Recruiting
talaromycosis
0 Actively Recruiting
Oropharyngeal Candidiasis
0 Actively Recruiting
HIV
155 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1
Blastomycosis
0 Actively Recruiting

Sporanox Reviews: What are patients saying about Sporanox?

5Patient Review
10/28/2007
Sporanox for Infection caused by Blastomyces Dermatitidis Fungus
3.7Patient Review
6/29/2009
Sporanox for Type of Infection caused by Histoplasmosis Fungus
I was diagnosed with histoplasmosis in my lungs in May 2007 after several trips to the hospital. Sporonox worked but the side effects got worse at first, with pain then nightmares. Now I experience fatigue, trouble sleeping and loss of interest.
3.7Patient Review
10/27/2010
Sporanox for Infection caused by Coccidioides Fungus
I am taking this medication to combat a fungal infection in my lungs, and it seems to be working well so far. I have not experienced any of the listed side effects, which is great. The only downside is that it doesn't taste very good.
3.7Patient Review
1/30/2014
Sporanox for Candidiasis Fungal Infection of the Oropharynx
Sporanox has been an effective treatment for me, though I have had to take it on and off for six years now. Every time I stop taking it, the sinus fungal symptoms come back. I am worried about potential liver and heart issues, but my doctors keep a check on me.
3.7Patient Review
9/1/2009
Sporanox for Fungal Infection of Toenails
It's been quite a while since I first started this treatment, and the infection still hasn't cleared up. That said, it has significantly improved. I'm hopeful that with more time it will be gone entirely.
3.7Patient Review
5/14/2009
Sporanox for Type of Infection caused by Histoplasmosis Fungus
This medication is effective, but very inconvenient to take. I have to time it around my other medications and can't have anything else to drink for an hour afterwards, which makes it difficult to work into my schedule.
3Patient Review
10/30/2008
Sporanox for Infection caused by Coccidioides Fungus
The taste is really awful, but it works.
1.7Patient Review
3/16/2014
Sporanox for Infection caused by the Fungus Scedosporium Apiospermum
I found this treatment to be more harmful than helpful.
1Patient Review
11/30/2012
Sporanox for Fungal Infection of Fingernails - Onychomycosis
I was given this drug to treat a fingernail fungus contacted from a nail salon. I took the medicine before going to bed and was awakened a few hours later with severe itching. When I went into my bathroom and turned on the light, I could not believe the swelling and redness. I had red hives from the top of my head to the soles of my feet.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about sporanox

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Which is better Sporanox or Lamisil?

"The LION study showed that terbinafine was more effective than itraconazole in treating onychomycosis."

Answered by AI

What are the side effects of the drug Sporanox?

", feeling anxious, nervous, or irritable

headache, increased blood pressure, rash, itching, nausea, vomiting, stomach pain, diarrhea, constipation, swelling, abnormal liver function or blood tests, fever, muscle or joint pain, unusual or unpleasant taste in your mouth, feeling anxious, nervous, or irritable"

Answered by AI

What is Sporanox used for?

"The Sporanox capsule is used to treat fungal infections in fingernails or toenails, while the Itraconazole tablet is only used to treat toenail fungal infections. This medicine kills the fungus or yeast and prevents its growth. You need a doctor's prescription to get this medicine."

Answered by AI

How long does it take Sporanox to work?

"It may take up to 6 months to grow a new fingernail, and up to 12 months to grow a new toenail. Therefore, you should not expect to see an improvement during your treatment, or for several months afterward. It is important to continue taking itraconazole even if you do not see any improvement."

Answered by AI

Clinical Trials for Sporanox

Image of The University of Alabama at Birmingham in Birmingham, United States.

Behavioral vs Mindfulness Treatments for Insomnia in HIV

50 - 99
All Sexes
Birmingham, AL
The goal of this clinical trial is to examine the effects of a telephone-delivered Brief Behavioral Treatment Insomnia (BBTI) versus a Brief Mindfulness Treatment (BMT) on cognitive and sleep outcomes in older adults with HIV. The main questions it aims to answer are: What are the effects of BBTI vs BMT on self-reported and observed sleep outcomes in older adults with HIV and insomnia up to 1-year post-intervention? What are the effects of BBTI vs BMT on self-reported and observed cognitive comes in older adults with HIV and insomnia up to 1-year post-intervention? What is the association between Alzheimer's Disease biomarkers and sleep and cognitive outcomes in older adults with HIV receiving BBTI vs BMT? Participants will: * Complete 4 weeks of telephone-delivered BBTI or BMT * Attend baseline, post-intervention, and 1-year post in-person visits for sleep and cognitive assessments * Have blood collected at all three time points
Waitlist Available
Has No Placebo
The University of Alabama at Birmingham (+1 Sites)Dr. Shameka L Cody, PhD, AGNP-C, PMHNP-BC, FAAN
Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL
The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.
Phase < 1
Waitlist Available
University of Alabama at Birmingham
Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC
This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.
Phase 1
Recruiting
University of North CarolinaCynthia L. Gay, MD
Have you considered Sporanox clinical trials? We made a collection of clinical trials featuring Sporanox, we think they might fit your search criteria.Go to Trials
Image of Center on Substance Use and Health in San Francisco, United States.

CHAMPION Intervention for Pre-exposure Prophylaxis Adherence

18 - 40
Male
San Francisco, CA
The goal of this randomized controlled trial is to pilot test new mobile health (mHealth) interventions to improve PrEP adherence among HIV-negative men who have sex with men (MSM) with mild to moderate methamphetamine use disorder (MUD). The CHAMPION intervention combines two mHealth tools-PrEPAPP and CBT4CBT-to address both HIV prevention and MUD treatment needs in this population. The study's specific aims are: * To evaluate the feasibility and acceptability of the CHAMPION intervention based on treatment retention and engagement rates. * To examine the preliminary efficacy the CHAMPION intervention to improve PrEP adherence, as measured by dried blood spot (DBS) tests compared to the waitlist control group.
Waitlist Available
Has No Placebo
Center on Substance Use and HealthGlenn-Milo Santos, PhD, MPH
Have you considered Sporanox clinical trials? We made a collection of clinical trials featuring Sporanox, we think they might fit your search criteria.Go to Trials
Image of UCSF in San Francisco, United States.

N-803 for HIV

18 - 70
All Sexes
San Francisco, CA
Even though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can change the nature of the latent reservoir and if this could help people control HIV without the need to take regular HIV medicine. This study is testing a drug called N-803. N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and natural killer (NK) cells. CD8+ T cells and NK cells are both crucial for eliminating infected cells. The drug is FDA-approved for the treatment of bladder cancer, but in this study the drug is being used experimentally for HIV.
Phase 2
Waitlist Available
UCSF
Image of Alabama CRS (Site ID: 31788) in Birmingham, United States.

Dasatinib + Quercetin for HIV

18+
All Sexes
Birmingham, AL
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Phase 2
Waitlist Available
Alabama CRS (Site ID: 31788) (+26 Sites)
Image of Yale University in New Haven, United States.

DynamiCare + Patient Navigation for Stimulant Use Disorder

18+
All Sexes
New Haven, CT
Justice-involved individuals face disproportionately high rates of stimulant use disorder and HIV, along with disrupted access to HIV treatment and prevention services like ART and PrEP. Contingency management (CM) is the most effective intervention for stimulant use, but its use in justice-involved populations has been limited by logistical and structural barriers. DynamiCare is an FDA-approved mobile app that delivers behavioral CM and has shown promise in reducing stimulant use, but its impact on HIV-related outcomes remains unknown. The RESTORE study (Recovery and Engagement for Stimulant Users on Re-entry) will evaluate whether combining DynamiCare with patient navigation (DynamiCare-plus) improves PrEP/ART initiation and reduces stimulant use among individuals recently released from justice settings. The R61 phase will assess feasibility, acceptability, and preliminary effectiveness among 40 participants. If milestones are met, the R33 phase will scale to a randomized controlled trial with 252 participants to assess effectiveness, implementation, and cost. This scalable, mobile approach has the potential to address a critical gap in care for a highly vulnerable population.
Waitlist Available
Has No Placebo
Yale University (+1 Sites)Ank Nijhawan, MD
Have you considered Sporanox clinical trials? We made a collection of clinical trials featuring Sporanox, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security